Capricor Therapeutics Statistics
Share Statistics
Capricor Therapeutics has 45.47M shares outstanding. The number of shares has increased by 26.23% in one year.
| Shares Outstanding | 45.47M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 1.75% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 39.96M |
| Failed to Deliver (FTD) Shares | 36 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 5.28M, so 11.62% of the outstanding shares have been sold short.
| Short Interest | 5.28M |
| Short % of Shares Out | 11.62% |
| Short % of Float | 13.2% |
| Short Ratio (days to cover) | 1.31 |
Valuation Ratios
The PE ratio is -5.88 and the forward PE ratio is -22.35.
| PE Ratio | -5.88 |
| Forward PE | -22.35 |
| PS Ratio | 5.2 |
| Forward PS | 11.1 |
| PB Ratio | 5.79 |
| P/FCF Ratio | -4.74 |
| PEG Ratio | n/a |
Enterprise Valuation
Capricor Therapeutics Inc. has an Enterprise Value (EV) of 121.86M.
| EV / Earnings | -5.47 |
| EV / Sales | 4.84 |
| EV / EBITDA | -5.3 |
| EV / EBIT | -5.06 |
| EV / FCF | -4.41 |
Financial Position
The company has a current ratio of 1.63, with a Debt / Equity ratio of 0.
| Current Ratio | 1.63 |
| Quick Ratio | 1.63 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.99% and return on capital (ROIC) is -96.94%.
| Return on Equity (ROE) | -0.99% |
| Return on Assets (ROA) | -0.38% |
| Return on Capital (ROIC) | -96.94% |
| Revenue Per Employee | 249.29K |
| Profits Per Employee | -220.67K |
| Employee Count | 101 |
| Asset Turnover | 0.43 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 206.68% in the last 52 weeks. The beta is 4.02, so Capricor Therapeutics 's price volatility has been higher than the market average.
| Beta | 4.02 |
| 52-Week Price Change | 206.68% |
| 50-Day Moving Average | 18.54 |
| 200-Day Moving Average | 8.76 |
| Relative Strength Index (RSI) | 38.59 |
| Average Volume (20 Days) | 3.55M |
Income Statement
In the last 12 months, Capricor Therapeutics had revenue of $25.18M and earned -$22.29M in profits. Earnings per share was $-0.83.
| Revenue | 25.18M |
| Gross Profit | 24.11M |
| Operating Income | -24.08M |
| Net Income | -22.29M |
| EBITDA | -23.01M |
| EBIT | -24.08M |
| Earnings Per Share (EPS) | -0.83 |
Balance Sheet
The company has $14.69M in cash and $2.24M in debt, giving a net cash position of $12.46M.
| Cash & Cash Equivalents | 14.69M |
| Total Debt | 2.24M |
| Net Cash | 12.46M |
| Retained Earnings | -159.37M |
| Total Assets | 92.95M |
| Working Capital | 65.35B |
Cash Flow
In the last 12 months, operating cash flow was -$25.60M and capital expenditures -$2.05M, giving a free cash flow of -$27.64M.
| Operating Cash Flow | -25.60M |
| Capital Expenditures | -2.05M |
| Free Cash Flow | -27.64M |
| FCF Per Share | -1.03 |
Margins
Gross margin is 95.75%, with operating and profit margins of -95.63% and -88.52%.
| Gross Margin | 95.75% |
| Operating Margin | -95.63% |
| Pretax Margin | -88.52% |
| Profit Margin | -88.52% |
| EBITDA Margin | -91.39% |
| EBIT Margin | -95.63% |
| FCF Margin | -109.79% |
Dividends & Yields
CAPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -6.24% |
| FCF Yield | -4.57% |
Analyst Forecast
The average price target for CAPR is $32.5, which is 144.2% higher than the current price. The consensus rating is "Buy".
| Price Target | $32.5 |
| Price Target Difference | 144.2% |
| Analyst Consensus | Buy |
| Analyst Count | 7 |
Stock Splits
The last stock split was on Jun 5, 2019. It was a backward split with a ratio of 1:10.
| Last Split Date | Jun 5, 2019 |
| Split Type | backward |
| Split Ratio | 1:10 |
Scores
| Altman Z-Score | 855.55 |
| Piotroski F-Score | 3 |